Viz.ai Wins 2018 Fierce Innovation Award: Healthcare Edition for Clinical Information Management
SAN FRANCISCO, Feb. 6, 2019
SAN FRANCISCO, Feb. 6, 2019 /PRNewswire/ -- Viz.ai has received the 2018 Fierce Innovation Award: Healthcare Edition for their Artificial Intelligence software, Viz LVO, which promises to reduce time to treatment, increase access and improve hospital finances. Viz LVO is the first FDA cleared AI-based clinical decision support software designed to analyze computed tomography (CT) images and automatically notify providers of a potential LVO stroke in their hospital network.
The Fierce Innovation Awards showcase outstanding innovations that are driving improvements and transforming the biotech, digital health, and pharma industries.
Clinical Information Management - Clinical information management supports decision making and ensures quality patient information at every touchpoint along the patient journey.
Erlanger Health System in Chattanooga, Tennessee, one of the busiest stroke centers in the world, was an early adopter in rolling out the Viz system throughout its network of 7 hospitals covering a service area of 50,000 square miles. "Viz LVO has truly transformed our stroke care in the detection of suspected LVO patients and helping our stroke team make faster treatment decisions," said Joseph Winick, FACHE, Lead Executive, Erlanger Innovation Center at Erlanger Health System. "Viz LVO has also allowed Erlanger to continue to be an early adopter in bringing the best possible care for our patients while transforming our business model demonstrating how artificial intelligence can drive ROI."
The Fierce Innovation Awards Committee sought the best companies with the most innovative technologies and services that have the greatest potential to save money, engage patients and revolutionize the healthcare industry. The winners of the Fierce Innovation Awards were selected by a distinguished panel of judges from renowned U.S. hospitals and healthcare systems.
"Fierce Healthcare provides healthcare executives with valuable insights into new innovations that can transform hospital finances while simultaneously improving patient care." said Dr. Chris Mansi, Viz.ai CEO. "To be recognized by healthcare executives from the top hospitals and healthcare systems around the country demonstrates the potential impact Viz.ai is having on patient care and hospital finances."
The winning software, Viz LVO, is a cloud-based AI software system that automatically analyzes CT scans for large vessel occlusions (LVO). It alerts neurovascular specialists of a suspected LVO, synchronizing care and ensuring that the right patient gets to the right doctor at the right time. This enables better care coordination across a hospital network, potentially increased contribution margin and potentially better patient outcomes.
Stroke is a leading cause of permanent disability, death and healthcare costs globally. According to the American Heart Association/American Stroke Association (AHA/ASA), stroke is the fifth leading cause of death in the U.S. and a leading cause of disability. When a stroke occurs, and the flow of oxygen-rich blood to a portion of the brain is blocked, 1.9 million brain cells die every minute; in the case of stroke, "Time is Brain."
FierceMarkets, a division of Questex, LLC, is a leader in B2B e-media, providing information and marketing services in the telecommunications, life sciences, healthcare and technology industries through its portfolio of email newsletters, websites, webinars and live events. Every business day, FierceMarkets' wide array of digital publications reaches more than 2 million executives in more than 100 countries.
About Viz.ai, Inc.
Viz.ai, is the leader in applied artificial intelligence in healthcare. Viz.ai's mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment and improve access to care. Viz.ai's flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat.
In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO, the first-ever computer-aided triage and notification software. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral perfusion image analysis.
Viz.ai is located in San Francisco and Tel Aviv and backed by leading Silicon Valley investors, including Kleiner Perkins, Google Ventures, Innovation Endeavors and DHVC.